<![CDATA[AQUATRECK ANIMAL HEALTH S.L. - News]]>Tue, 15 Sep 2026 14:08:34 +0200Weebly<![CDATA[Our novel sea lice vaccine research leaps forward to next stage and makes waves in aqua media.]]>Thu, 28 Mar 2024 12:54:50 GMThttps://www.aquatreck.com/news/our-novel-sea-lice-vaccine-research-leaps-forward-to-next-stage-and-makes-waves-in-aqua-media
🌟 Innovation Through Collaboration: A Leap Forward
       in Sea Lice Vaccine Research 🌟

All the Team in AQUATRECK ANIMAL HEALTH S.L, we are thrilled to share a pivotal milestone on the development of a groundbreaking vaccine against sea lice, that is making news with the project successfully progressing to its next phase, thanks to almost £50,000 in funding from Sustainable Aquaculture Innovation Centre (SAIC) in collaboration with the University of Stirling’s Institute of Aquaculture and Moredun Scientific.  This milestone is a testament to the promising outcomes of our initial proof-of-concept phase, which unveiled that a novel vaccine technology based on yeast expression technology can create recombinant proteins that can trigger an immune response and create elevated antibody levels in the bloodstream of fishthat aim to impair sea lice development and potentially reduce the number of parasite offspring by mature sea lice.

AQUATRECK ANIMAL HEALTH S.L novel yeast expression platform can support scalling up of vaccine production with the aim to address the global aquaculture challenge posed by sea lice, with costs amounting to up to $1 billion per year.  The essence of our project lies not only in the innovative approach to vaccine development but also in the power of collaboration. By bringing together the expertise and dedication of our partners, we are paving the way for a solution that promises to enhance fish health and welfare significantly, reduce environmental impact, and create a more economically viable future for the salmon farming sector. The team is using advanced recombinant expression technology for injection vaccination and, if successful, the technology could be scaled up to make mass antigens available to later be applied via salmon feeds as an oral vaccine.
We extend our heartfelt thanks to Sustainable Aquaculture Innovation Centrefor their financial support and faith in our project's potential. 
Our gratitude also goes out to Dr Sean Monaghan and all our partners at the University of Stirling’s Institute of Aquaculture and Moredun Scientific, whose expertise has been invaluable in reaching this stage of research. Together, we are not just aiming to tackle one of aquaculture's biggest challenges but also to set a precedent for how collaboration can lead to meaningful innovation.
As we move forward, AQUATRECK ANIMAL HEALTH S.L remains committed to this project's success and the broader goal of promoting sustainable aquaculture globally. We look forward to sharing more milestones and, ultimately, the positive impact of our vaccine on the aquaculture industry.  Special thanks to the aquaculture media that brought forward the news and SAIC Team for making the announcement.  Thank you to everyone involved for your dedication, expertise, and vision. Together, we are making a difference.
]]><![CDATA[Juan Carlos Castillejo joins Aquatreck Board]]>Thu, 28 Mar 2024 12:40:15 GMThttps://www.aquatreck.com/news/juan-carlos-castillejo-joins-aquatreck-board
🌟 Exciting Announcement from AQUATRECK ANIMAL    
​       HEALTH S.L.🌟

It is a great honor and pleasure to welcome Juan Carlos Castillejo in the Board of Directors of AQUATRECK ANIMAL HEALTH S.L. to support our dynamic fish vaccine company with his strategic thinking in the implementation of our growth strategy. 🚀

​Juan Carlos is a leader in animal health with extensive professional experience in senior management of animal health biopharmaceutical companies.

​Juan Carlos holds a degree in Biological Sciences from the Universidad Autónoma de Madrid, a degree in Veterinary Medicine from the Universidad Complutense de Madrid and a Master's degree in Business Administration from the Instituto de Empresa, joined the MSD Animal Health in 2013 to take up the position of Managing Director in Spain and in 2014 he became Managing Director of the Iberia cluster. including Portugal.  

Juan Carlos Castillejo was president of VETERINDUSTRIA for more than 10 years, he held the management for Spain and Portugal of the two most important multinationals in the animal health market, Zoetis (formerly Pfizer Animal Health) and MSD Animal Health were he closed his professional career after ten years as Managing Director of MSD Animal Health in Spain and Portugal at the end of 2022. 

In this position he led the digital transformation of the organization and adapted the company, developing the capabilities required for the future. One of the main achievements of his business career was the development and commercialization of the world's first bluetongue vaccine. Juan Carlos joined Grupo ZENDAL's steering committee as a strategic advisor in May 2023.
]]><![CDATA["10 reasons why we should vaccinate our fish"]]>Thu, 31 Aug 2023 06:30:06 GMThttps://www.aquatreck.com/news/10-reasons-why-we-should-vaccinate-our-fish"10 Reasons why we should vaccinate our fish" 
Aquaculture is a vital industry, providing a significant portion of the world's seafood. Vaccinating fish offers numerous benefits, similar to vaccinating other animals. Let’s explore 10 compelling reasons to consider fish vaccination. Join the movement! Stay informed about the latest advancements in fish vaccination. Collaborate with researchers, veterinarians, and industry experts. Together, we can create a healthier, more sustainable future for aquaculture. Contact us! Connect with us on LinkedIn for updates and discussions!
​Follow AQUATRECK in LinkedIN for more updates and see the full video in the LinkedIN here:
Picture
]]><![CDATA[AQUATRECK in AE22 in Rimini]]>Fri, 23 Sep 2022 14:59:46 GMThttps://www.aquatreck.com/news/aquatreck-in-ae22-in-riminiIt will be a great pleasure to meet friends and colleagues in AQUATRECK ANIMAL HEALTH S.L stand (No: 58) in Aquaculture Europe 2022 in Rimini, Italy next week.  We have exciting news from our research team to share and discuss!  Join us to discuss on Novel technology vaccines that are multivalent, customised and cost-effective. We work Together to combat the major fish diseases.
​Follow us in LinkedIN for more updates: www.linkedin.com/company/19090697/admin/
Contact our team
Picture
Picture
]]><![CDATA[Aquatreck in the Media]]>Mon, 08 Apr 2019 16:06:55 GMThttps://www.aquatreck.com/news/aquatreck-launch-in-the-mediaAQUATRECK launch is making headlines in the Aquaculture Media. We would like to thank the editorial teams and all the friends in the sector for supporting us!
​Follow our LINKEDin page to see the articles and find more news.
Picture
]]><![CDATA[AQUATRECK Launch]]>Wed, 20 Mar 2019 07:00:00 GMThttps://www.aquatreck.com/news/aquatreck-launchPRESS Release (EN) (ES)
CZ VACCINES S.A established in Spain and MARINNOVAC Limited established in Ireland announced today the incorporation in OPorriño. Pontevedra Spain of a new Aqua pharmaceutical company under the name: “AQUATRECK ANIMAL HEALTH S.L.”
 
Prof. Patrick Smith MARINNOVAC chairman said: “The mission of AQUATRECK is to fast track innovative fish & shrimp disease prevention strategies by building effective open collaboration alliances of top talented teams to serve the global aquaculture industry’s sustainable future” 
 
AQUATRECK aims to support global aquaculture development providing autogenous, experimental and licensed vaccines and novel, innovative, reliable, accurate diagnostic services for the fish and shrimp farming industry. 
 
Andrés Fernández Álvarez-Santullano, CEO of CZ Vaccines S.A mentioned: “We have long experience as CMO GMP producers of fish vaccines for the last 25 years and we decided to focus to accelerate the sustainable global aquaculture growth by preventing the major fish and shrimp diseases so we launch today AQUATRECK a new dynamic open innovation aquatic health company” 
 
Dr. Panos Christofilogiannis AQUATRECK Director indicated: “AQUATRECK has long experience in fish vaccine development based on close collaboration and continuous interaction with fish farmers in order to develop comprehensive health management strategies. AQUATRECK has top level viral vaccine research and development facilities in Cambridge, UK, sub-unit fish vaccine research and development facilities in Dortmund, Germany, state of the art GMP Fish vaccine manufacturing facilities in Spain and close links with a vibrant network of fish immunology and pathology scientists around the world".

​
]]>